-
Article
Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer
Cisplatin-based chemotherapy followed by radical cystectomy (RC) is recommended in patients with muscle-invasive bladder cancer (MIBC). However, up to 50% of patients are cisplatin ineligible. The aim of this ...
-
Article
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma
Standard-of-care management of renal cell carcinoma (RCC) indisputably relies on surgery for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease, but a grey area remains, en...
-
Article
Open AccessAssociation of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer
To assess the association of patient age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer (MIBC).
-
Article
Partial versus radical nephrectomy in very elderly patients: a propensity score analysis of surgical, functional and oncologic outcomes (RESURGE project)
To compare the outcomes of PN to those of RN in very elderly patients treated for clinically localized renal tumor.
-
Article
Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer
Purpose Sunitinib is a vascular endothelial growth factor receptor (VEGFR) inhibitor with antitumor activity against bladder cancer. We hypothesized that treatment with sunitinib may decrease progression or recur...
-
Article
Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA Collaborative Group)
To compare the outcomes of robotic radical nephrectomy (RRN) to those of laparoscopic radical nephrectomy (LRN) for large renal masses.
-
Article
Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer
Background Despite definitive local therapy, patients with high-risk prostate cancer have a significant risk for local and distant failure. To date, no systemic therapy given prior to surgery has been shown to im...
-
Article
Open AccessAutophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin)
Macroautophagy is a catabolic process that can mediate cell death or survival. Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) treatment (TR) is known to induce autophagy. H...
